Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease by William Seiple, Danna Jennings, Richard B. Rosen, Leona Borchert, Lee Canale, Nora Fagan, Mark Forrest Gordon

Get full text

Minimal Clinically Important Difference in Parkinson’s Disease as Assessed in Pivotal Trials of Pramipexole Extended Release by Robert A. Hauser, Mark Forrest Gordon, Yoshikuni Mizuno, Werner Poewe, Paolo Barone, Anthony H. Schapira, Olivier Rascol, Catherine Debieuvre, Mandy Fräßdorf

Get full text

Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case–control study using European electronic health records by Johan van Der Lei, Robert Stewart, Pieter Jelle Visser, Talita Duarte-Salles, Myriam Alexander, David Ansell, Alessandro Pasqua, Francesco Lapi, Paul Avillach, Lars Pedersen, Gayan Perera, Mark Forrest Gordon, Miguel Angel Mayer

Get full text

Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease by Samuel Frank, Karen E. Anderson, Hubert H. Fernandez, Robert A. Hauser, Daniel O. Claassen, David Stamler, Stewart A. Factor, Joohi Jimenez-Shahed, Hadas Barkay, Amanda Wilhelm, Jessica K. Alexander, Nayla Chaijale, Steve Barash, Juha-Matti Savola, Mark Forrest Gordon, Maria Chen

Get full text